Metabolic & Cardiometabolic
ezetimibe decreases cardiovascular disease
Part of: 💊 statins, 💊 ezetimibe
🧭 Read this score with how it was built in mindWe re-read the original papers and corrected what they actually say
One large network analysis had been recorded as high quality. Re-reading it, the paper's own certainty table rates every one of its clinical-outcome comparisons as low certainty; only its cholesterol-level comparisons are rated high. We now record it the way its authors do. The two landmark trials behind this claim are unchanged and still support it.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Ezetimibe added to a statin reduces major cardiovascular events post-ACS (IMPROVE-IT) - modest absolute effect (HR 0.94, ~2% over 7y, NNT ~50), proportional to the extra LDL reduction (consistent with 'lower LDL by any mechanism'). No mortality benefit.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators 2015 · N Engl J Med | RCT | supports | high | IMPROVE-IT NEJM paywalled; ARR 2.0%/7y (LDL 53.7 vs 69.5); landmark holds |
| Mahmoud A, Mohamed Salamah H, Rezq H, Al-Mohtasib Y, Ashraf Salah Ahmed A, Abdelraouf MR, Amin AM, Ibrahim AA, Adel Mohammed Y, Abdelwahab OA, AlBarakat MM, Elshenawy S, Abu Suilik H, Abdelazeem B 2025 · Proc Bayl Univ Med Cent | meta-analysis | mixed | moderate | FT 47-RCT: beats double-dose statin on LDL but NO diff in MI/mortality/stroke + more severe AEs; lipid-surrogate not events |
| Zhao X, Zheng S, Tang C, Chen J, Shi C, Yuan T, Liu X, Yang R, Zhi Y, Wang S 2026 · Cardiovascular drugs and therapy | meta-analysis | supports | low | Network meta-analysis of 18 randomised trials in 89,717 people with diabetes. Adding ezetimibe cut major adverse cardiovascular events by 18% against placebo on the same background statin (RR 0.82, 95% CI 0.74-0.91) and myocardial infarction by 23% (RR 0.77, 0.63-0.95); ezetimibe and evolocumab were the only two of fourteen agents whose myocardial-infarction reduction reached significance. Every ezetimibe trial here is an add-on-to-statin design. The authors rate their own certainty in this comparison as low, downgraded for heterogeneity. |
| He H, Tang J, Yan VKC, Blais JE, Wong CK, Tam MTK, Yiu HHE, Tse HF, Chan EWY 2026 · The Lancet regional health. Western Pacific | observational | supports | moderate | Propensity-matched cohort (n=1,452 combo vs 5,808 high-intensity statin monotherapy): moderate-intensity statin+ezetimibe associated with significantly lower risk of incident PCI/CABG (HR 0.57, 95% CI 0.36-0.91) plus greater LDL-C reduction |
| Kataoka Y, Nicholls SJ, Kitahara S, Katasako-Yabumoto A, Funabashi S, Mitsui K, Murai K, Iwai T, Sawada K, Matama H, Honda S, Takagi K, Fujino M, Yoneda S, Nakao K, Asaumi Y, Noguchi T 2026 · Journal of clinical lipidology | observational | supports | moderate | Retrospective cohort of 780 CAD patients achieving LDL-C <1.4 mmol/L post-PCI: those who developed MACE were less likely to be on ezetimibe (45.8% vs 63.2%, p=0.023) than those without MACE. |
| Liu HH, Liu ZH, Chen SS, Zhu CG, Li JJ 2026 · American journal of cardiovascular drugs : drugs, devices, and other interventions | observational | supports | moderate | Narrative review of ezetimibe evidence in ASCVD: monotherapy lowers LDL-C ~17-26% and reduces MACE vs placebo; adding ezetimibe to statin achieves greater LDL-C reduction, reduces plaque burden, and lowers CV event incidence vs statin alone |
| Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald E 2021 · J Am Coll Cardiol | RCT | supports | high | IMPROVE-IT: ezetimibe+statin CV benefit consistent across baseline LDL strata |
| Sajid EU, Azeem MH, Fatima A, Jafri SM, Hassan D, Ibrahim T, Manjee KZ, Ahmed SR, Ali T, Shakeel R, Usman M, Mahato RK, Bawa D 2026 · Clinical cardiology | meta-analysis | mixed | low | Systematic review/meta-analysis (9 studies, 179,621 patients post-PCI): moderate-intensity statin+ezetimibe vs high-intensity statin monotherapy showed no significant MACE difference (RR 0.96, 95% CI 0.81-1.12), though modest reductions in |
| Vuorio A, Kovanen PT, Strandberg T 2026 · Annals of medicine | observational | supports | low | Commentary discussing the EWTOPIA 75 trial, which found ezetimibe monotherapy (without statin) reduced ASCVD events in adults ≥75y without prior CAD; proposes mechanistic explanations (age-related rise in cholesterol absorption). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.